Erytop Gel contains Clindamycin 1% w/w, a topical antibiotic indicated for the treatment of acne vulgaris. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby exerting a bacteriostatic effect against Propionibacterium acnes and other susceptible anaerobic bacteria involved in acne pathogenesis. Erytop Gel is applied topically to affected areas once or twice daily as directed by a healthcare professional. The formulation facilitates targeted delivery of clindamycin to the pilosebaceous units, reducing bacterial colonization and inflammation, which contributes to the improvement of acne lesions, including inflammatory papules and pustules. It is generally well tolerated, with the most common adverse effects being local skin irritation, dryness, erythema, and peeling at the application site. Patients are advised to avoid contact with eyes, mouth, and mucous membranes. Use during pregnancy and lactation should be under medical supervision. Erytop Gel should be used as part of a comprehensive acne management plan, including appropriate skin hygiene and avoidance of comedogenic products. Resistance to clindamycin may develop with prolonged use; therefore, therapy duration should be limited and monitored by a healthcare provider.